



# UNSEEN COSTS OF ECZEMA

Eczema is a highly variable inflammatory skin disease that affects individuals of all ages and often contributes to physical, emotional, and financial distress. Despite its prevalence, it remains a commonly underestimated and misunderstood condition, with some of its most excruciating burdens hidden from view.

**Millions affected costing billions of dollars**

**33 MILLION**

Americans of all ages are living with eczema




Costing the U.S.

**\$5.3 BILLION/YEAR**

in direct and indirect costs including **\$619 million/year** in lost productivity

**Life-altering symptoms**



**More than skin deep**

Eczema is associated with significantly higher rates of:



**Allergic rhinitis**  
46%



**Food allergies**  
42%



**Asthma**  
35%



**Anxiety**  
26%



**Depression**  
22%



**Persistent skin infections**  
16%

**Treatment efficacy is individualized and changes over time**



No two affected individuals are the same. Symptoms, presentations, and quality of life impacts vary from person to person and are constantly evolving. Treatments that work for one person today may not work for that same person, or for others, tomorrow. Current options include:

- » Over-the-counter skin care products (topical)
- » Prescription corticosteroids (topical and oral)
- » Prescription topical non-steroidal agents
- » Systemic immunosuppressing and immune-targeting agents (oral)
- » Phototherapy
- » Biologics (injectable)

**Few patients experience total symptom relief or sustained control from existing treatments**

**58%**

*mixed response* to available therapies

**44%**

*discontinued* prescribed medications for eczema

**16%**

*harmed* by available therapies

**Only 12%**

*satisfied* with their current therapy

SOURCES More Than Skin Deep Survey. Conducted 2019 with 1,508 individuals from the U.S. and 57 other countries (72% patients; 28% caregivers)

Silverberg JI, Chiesa Fuxench ZC, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, Simpson EL, Ong PY. Content and construct validity, predictors, and distribution of self-reported atopic dermatitis severity in US adults. *Ann Allergy Asthma Immunol.* 2018 Dec;121(6):729-734.

**Better, more personalized treatment options could improve outcomes and reduce costs.**

**morethanskindeep-eczema.com**